FAQ

Tykerb

 

Topic mentions per year

Topic mentions per year

2006-2016
051020062016

Related topics

Related topics

2 relations

Broader (2)

lapatiniblapatinib ditosylate

Related mentions per year

Related mentions per year

1979-2018
197019801990200020102020
Tykerb
lapatinib
lapatinib ditosylate

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2012
2012
Human metabolism of lapatinib, a dual kinase inhibitor: implications for hepatotoxicity.
Lapatinib (Tykerb, Tyverb) is an important orally active dual tyrosine kinase inhibitor efficacious in combination therapy for… (More)
  • figure 2
  • table 1
  • table 3
  • figure 3
  • table 2
Is this relevant?
2010
2010
Antibody–drug conjugates for cancer: poised to deliver?
In July this year, Genentech submitted a biologic license application to the US Food and Drug Administration (FDA) for the… (More)
  • table 1
Is this relevant?
2010
2010
Mechanism-based inactivation of cytochrome P450 3A4 by lapatinib.
Fatalities stemming from hepatotoxicity associated with the clinical use of lapatinib (Tykerb), an oral dual tyrosine kinase… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2010
2010
Lapatinib and erlotinib are potent reversal agents for MRP7 (ABCC10)-mediated multidrug resistance.
In recent years, a number of TKIs (tyrosine kinase inhibitors) targeting epidermal growth factor receptor (EGFR) family have been… (More)
Is this relevant?
Highly Cited
2009
Highly Cited
2009
Suppression of HER2/HER3-mediated growth of breast cancer cells with combinations of GDC-0941 PI3K inhibitor, trastuzumab, and pertuzumab.
PURPOSE Oncogenic activation of the phosphatidylinositol 3-kinase (PI3K) signaling pathway is prevalent in breast cancer and has… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Highly Cited
2008
Highly Cited
2008
Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2.
Lapatinib is active at the ATP-binding site of tyrosine kinases that are associated with the human epidermal growth factor… (More)
  • table 1
  • table 2
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
Highly Cited
2008
Highly Cited
2008
The role of efflux and uptake transporters in [N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine (GW572016, lapatinib) disposition…
Lapatinib [N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine… (More)
  • table 1
  • table 2
  • figure 1
  • table 3
  • figure 2
Is this relevant?
Highly Cited
2008
Highly Cited
2008
Overexpression of fatty acid synthase gene activates HER1/HER2 tyrosine kinase receptors in human breast epithelial cells.
OBJECTIVES More than 50 years ago, we learned that breast cancer cells (and those of many other types of tumour) endogenously… (More)
Is this relevant?
2008
2008
Resistance in Cancer Cells by Inhibiting the Activity of Lapatinib (Tykerb, GW572016) Reverses Multidrug
Lapatinib is active at the ATP-binding site of tyrosine kinases that are associated with the human epidermal growth factor… (More)
  • table 1
  • table 2
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
Highly Cited
2007
Highly Cited
2007
Assessment of epidermal growth factor receptor (EGFR, ErbB1) and HER2 (ErbB2) protein expression levels and response to lapatinib (Tykerb, GW572016) in an expanded panel of human normal and tumour…
OBJECTIVE Lapatinib (Tykerb, GW572016), a potent inhibitor of the catalytic activities of epidermal growth factor receptor (EGFR… (More)
Is this relevant?